Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GeNeuro Phase IIb Launch And Partner's Equity Investment

This article was originally published in Scrip

Executive Summary

GeNeuro SA. has begun its proof-of-concept Phase IIb study, CHANGE-MS, with lead product GNbAC1, an antibody targeting the protein MSRV-Env expressed in multiple sclerosis (MS). Servier, the company's development partner, has also exercised its equity investment option to become a minority shareholder in GeNeuro by buying shares from existing shareholder Eclosion2.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst